Archer Materials Limited (ASX: AXE) has further progressed its biochip development by establishing essential chip testing operations in a semiconductor fabrication environment.
The company says it is strategically growing its capability in semiconductor production operations that are essential to the development and commercialisation of its biochip technology.
The company previously announced that it has the ability to analyse the individual materials in the components of the biochip and it has now progressed to the stage where it has established testing and measurement for the chips themselves.
The company recently expanded its access to institutional deep tech infrastructure to analyse and characterise the material properties of its devices. The chip testing capabilities recently established are an integral part of prototyping and biochip operation, whereby testing occurs after the chip component assembly to assess operation.
This new capability provides the high-quality and reliable technical specifications necessary for Archer’s future patent applications. The establishment of semiconductor chip testing allows Archer to reach a number of biochip development milestones, including the fabrication of graphene transistors and their operation at the limits of what can be achieved technologically.
CEO, Dr Mohammad Choucair, said Archer’s technologies are complementary; the company is developing advanced chips in the same semiconductor fabrication environment. Importantly, the chip testing workstations can also be configured to test chip devices relevant to the Company’s 12CQ quantum computing qubit processor development.
The establishment of in-house semiconductor chip testing and measurement is a key operational requirement that is necessary to build our technology,” Dr Choucair said.
“This will allow the company to meet a number of milestones in the development of multiple chip types, including its biochip and also quantum computing chip.”
